Capstan announces $175M oversubscribed Series B financing to support CPTX2309 to early clinical proof-of-concept in autoimmune disorders.

Capstan Therapeutics launched today with $165m in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy.

Capstan’s initial focus is the development of in vivo chimeric antigen receptor, or CAR T, therapies. CAR T-drugs are currently made from a patient’s own T cells, which are engineered in a lab ...

Capstan Therapeutics has launched with $165 million for in vivo cell engineering to treat disease. The start-up’s technology is based on research from the University of Pennsylvania, with ...

Capstan is combining surgical robots with catheter-based technology to provide a less invasive option for open heart surgery. The US-based startup will initially target mitral valve replacement ...

SAN DIEGO, September 26, 2024--Capstan announced it will present preclinical data on lead in vivo chimeric antigen receptor (CAR)-T candidate, CPTX2309, at ACR Convergence 2024.

The $31.4 million investment Capstan Medical Inc. recently received in its Series B funding round will allow the company to make headway in its efforts to use a catheter-based, robotic delivery ...

Capstan Medical has reeled in $110 million to continue its mission of bringing robotic surgery to a previously untouched sector of medicine: the replacement of cardiac valves to treat structural ...

Going forward, Capstan aims to grow its engineering, clinical development and operations teams with an eye on preparing for the first human clinical trials of its own valve and delivery system.